Home Online Features U.S. FDA approves Celltrion's OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®
U.S. FDA approves Celltrion’s OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®
Hand-out
Press Releases
March 9, 2025

U.S. FDA approves Celltrion’s OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®

By Celltrion

OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDARegulatory approval for interchangeability was supported by positive phase III data demonstrating comparable efficacy and safety profile with

bradford

The Bradford Era

email
Local & Social